SRC and Ewing sarcoma: A Src inhibitor, dasatinib, was previously shown to inhibit Ewing sarcoma growth (Berning et al., 2018; Timeus et al., 2008), although these studies used higher doses of dasatinib than the dose used to detect the rescue of growth arrest by GDF6 silencing (Figure 4O, dasatinib used at 50 nM).